NuVision: Funding, Investors & Team (Sep 2026)
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
NuVision has raised $2.5M across 1 funding round on record, the most recent an undisclosed round of $2.5M announced in Jul 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NuVision Company Profile and Key Stats
Latest funding round on record: Jul 2021.
NuVision Funding Rounds
NuVision Founders and Leadership Team
No contact details are on record for this team yet.
NuVision Funding Compared to Other Biotechnology Startups
NuVision's latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NuVision in Biotechnology and Nottingham
Companies Similar to NuVision
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
NuVision Funding FAQs
What does NuVision do?
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
How much funding has NuVision raised?
NuVision has raised $2.5M across 1 round on record. The most recent is an undisclosed round of $2.5M announced in Jul 2021.
When did NuVision last raise funding?
NuVision's most recent funding round on record is an undisclosed round of $2.5M, announced in Jul 2021.
Who is the CEO of NuVision?
Rosie Cunningham Thomas is listed as CEO at NuVision.
Where is NuVision headquartered?
NuVision is based in Nottingham, United Kingdom.
How many employees does NuVision have?
NuVision is in the 11-50 employee band.
How does NuVision's funding compare to other Biotechnology startups?
NuVision's latest round of $2.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NuVision Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NuVision is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.